CN1233389C - 一种抗癌参芪扶正中药制剂及制备方法 - Google Patents
一种抗癌参芪扶正中药制剂及制备方法 Download PDFInfo
- Publication number
- CN1233389C CN1233389C CN 200310103214 CN200310103214A CN1233389C CN 1233389 C CN1233389 C CN 1233389C CN 200310103214 CN200310103214 CN 200310103214 CN 200310103214 A CN200310103214 A CN 200310103214A CN 1233389 C CN1233389 C CN 1233389C
- Authority
- CN
- China
- Prior art keywords
- preparation
- anticancer
- radix
- chinese medicine
- shenqi fuzheng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 53
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims description 71
- 229940107666 astragalus root Drugs 0.000 title abstract 3
- 238000005728 strengthening Methods 0.000 title abstract 2
- 239000002398 materia medica Substances 0.000 title 1
- 239000007788 liquid Substances 0.000 claims abstract description 21
- 239000008187 granular material Substances 0.000 claims abstract description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 15
- 235000008434 ginseng Nutrition 0.000 claims abstract description 15
- 239000006187 pill Substances 0.000 claims abstract description 10
- 235000020357 syrup Nutrition 0.000 claims abstract description 10
- 239000006188 syrup Substances 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 45
- 239000008687 shenqi fuzheng Substances 0.000 claims description 43
- 239000000843 powder Substances 0.000 claims description 39
- 230000008569 process Effects 0.000 claims description 21
- 238000001035 drying Methods 0.000 claims description 18
- 239000003826 tablet Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000002674 ointment Substances 0.000 claims description 15
- 241000208340 Araliaceae Species 0.000 claims description 13
- 241000628997 Flos Species 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 13
- 241000180649 Panax notoginseng Species 0.000 claims description 13
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 13
- 241001250596 Pleione Species 0.000 claims description 13
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 13
- 210000000582 semen Anatomy 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 235000020374 simple syrup Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- -1 drying Substances 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 235000008504 concentrate Nutrition 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 35
- 210000004369 blood Anatomy 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 16
- 230000006870 function Effects 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 7
- 230000036737 immune function Effects 0.000 abstract description 6
- 230000007812 deficiency Effects 0.000 abstract description 4
- 208000032839 leukemia Diseases 0.000 abstract description 4
- 239000003390 Chinese drug Substances 0.000 abstract 4
- 244000131316 Panax pseudoginseng Species 0.000 abstract 3
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 241000031023 Amana edulis Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 244000077995 Coix lacryma jobi Species 0.000 abstract 1
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 241001632410 Eleutherococcus senticosus Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 241000157511 Oldenlandia Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- 229940107131 ginseng root Drugs 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- 230000037396 body weight Effects 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 8
- 238000010171 animal model Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000012449 Kunming mouse Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 229960000796 barbital sodium Drugs 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别及剂型 | 例数 | 瘤体重(g) | 抑制率 |
生理盐水组环磷酰胺组低剂量组高剂量组 | 30303030 | 1.6500±0.14860.6450±0.1173**1.2790±0.1607*1.0800±0.1527* | 60.920.934.5 |
组别及剂型 | 例数(N) | 瘤体重(g) | 抑制率 |
生理盐水组低剂量组高剂量组环磷酰胺组 | 30303030 | 1.6967±0.14181.3593±0.1223*1.1250±0.1826*0.8147±0.1644** | 20.133.451.7 |
组别及剂型 | 例数(N) | 廓清指数 |
生理盐水组低剂量组高剂量组 | 101010 | 0.0054±0.00170.0475±0.0399**0.0819±0.0354** |
组别及剂型 | 例数(N) | 廓清指数 |
生理盐水组低剂量组高剂量组 | 101010 | 0.065±0.02940.072±0.00280.086±0.0031 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310103214 CN1233389C (zh) | 2003-10-30 | 2003-10-30 | 一种抗癌参芪扶正中药制剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310103214 CN1233389C (zh) | 2003-10-30 | 2003-10-30 | 一种抗癌参芪扶正中药制剂及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1539458A CN1539458A (zh) | 2004-10-27 |
CN1233389C true CN1233389C (zh) | 2005-12-28 |
Family
ID=34333242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200310103214 Expired - Fee Related CN1233389C (zh) | 2003-10-30 | 2003-10-30 | 一种抗癌参芪扶正中药制剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1233389C (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100348259C (zh) * | 2005-11-07 | 2007-11-14 | 胡建平 | 一种提高免疫力的药物组合物及其制备方法和应用 |
CN100431586C (zh) * | 2006-12-08 | 2008-11-12 | 胡冬林 | 一种治疗癌症的胶囊 |
CN102847064B (zh) * | 2012-08-31 | 2014-12-24 | 苏捷 | 抑制恶性肿瘤转移的中药 |
CN103860660B (zh) * | 2012-12-14 | 2016-12-21 | 陕西郝其军制药股份有限公司 | 一种治疗急慢性白血病的药物及其制备方法 |
CN104367945A (zh) * | 2014-11-06 | 2015-02-25 | 李俊 | 一种用于辅助肝癌介入治疗的药物 |
CN105535501A (zh) * | 2016-01-22 | 2016-05-04 | 宋秀磊 | 一种治疗癌症的中药 |
CN106474421B (zh) * | 2016-10-11 | 2019-11-08 | 南方医科大学 | 一种治疗结直肠癌的中药组合物及其应用 |
CN108354184A (zh) * | 2017-12-28 | 2018-08-03 | 防城港圣保堂制药有限公司 | 一种用于癌症食疗的人参芡实粉及其制备方法 |
CN109432207A (zh) * | 2018-11-09 | 2019-03-08 | 汉寿县新运堂医药科技有限公司 | 抗癌中药制剂 |
CN111358914A (zh) * | 2020-04-07 | 2020-07-03 | 袁能忍 | 一种治疗白血病、肿瘤、艾滋病和衰老的组合物及其应用 |
CN114848786B (zh) * | 2022-04-29 | 2024-01-16 | 江西永昇制药股份有限公司 | 一种抗癌、增加免疫力的复方三参汤 |
-
2003
- 2003-10-30 CN CN 200310103214 patent/CN1233389C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1539458A (zh) | 2004-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1233389C (zh) | 一种抗癌参芪扶正中药制剂及制备方法 | |
CN1839944A (zh) | 降脂颗粒组合物及其制备方法 | |
CN1765392A (zh) | 一种补血调经,止血安胎的中药复方制剂及其制备方法 | |
CN103386078B (zh) | 一种中药组合物在制备治疗结肠癌药物中的应用 | |
CN101091769B (zh) | 一种治疗和预防食道癌、胃癌的药物及其制备方法 | |
CN1686501A (zh) | 一种治疗小儿腹泻的中药复方制剂及其制备方法 | |
CN110934924A (zh) | 一种中药骨髓生血组合物及其应用 | |
CN103520405A (zh) | 一种具有清热滋阴润燥、益气养血、润肠通便功能的纯中药养生制剂 | |
CN1050292C (zh) | 抗癌药物及其制备方法 | |
CN102430008B (zh) | 治疗胃肠疾病中药组合物及其制备方法 | |
CN1513497A (zh) | 一种调节免疫的组合物药物及其制备方法 | |
CN1879755A (zh) | 用于制备***疾病药物的中药组合物 | |
CN100352471C (zh) | 治疗继发性贫血、缺铁性贫血的药物及其制备方法 | |
CN1943661A (zh) | 一种中药组合物及其制备方法 | |
CN1136939A (zh) | 一种能治愈乙型肝炎的中药制剂及其配制技术 | |
CN1158091C (zh) | 一种治疗肺癌的中药组合物 | |
CN1931352A (zh) | 一种中药组合物及其制备方法 | |
CN102836315A (zh) | 一种预防调理转归肿瘤的中药组合物及其制备方法 | |
CN1256083C (zh) | 一种益气补血药物及其制备方法和应用 | |
CN1233416C (zh) | 一种治疗小儿消化不良的复方胃蛋白酶散剂及其制备方法 | |
CN108815301A (zh) | 具有促白细胞生成功效的组合物及其制备方法 | |
CN1042495C (zh) | 一种益气消癌升高白细胞的药物及其制备方法 | |
CN1931285B (zh) | 一种中药组合物及其制备方法 | |
CN101579495B (zh) | 一种中药组合物在制备治疗慢性胃炎药物中的应用 | |
CN1066057C (zh) | 治疗和预防恶性肿瘤的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PP01 | Preservation of patent right |
Effective date of registration: 20070618 Pledge (preservation): Preservation |
|
PD01 | Discharge of preservation of patent |
Date of cancellation: 20080618 Pledge (preservation): Preservation registration |
|
ASS | Succession or assignment of patent right |
Owner name: LIAOYUAN YULONGYA PHARMACEUTICAL CO.LTD. Free format text: FORMER OWNER: LIAOYUAN YADONG MEDICINE CO., LTD., JILIN PROVINCE Effective date: 20080926 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080926 Address after: Jilin city of Liaoyuan province Yiyang Friendship Road No. 5 Patentee after: LIAOYUAN YULONGYADONG PHARMACEUTICAL Co.,Ltd. Address before: No. 33 Youyi Road, Jilin, Liaoyuan Patentee before: Jilin Liaoyuan Yadong Pharmaceutical Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051228 |